Alpha Teknova TKNO
Alpha Teknova FY 2021: revenue $36.9M; diluted EPS −$0.61
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-22-004176
- Document
- 10-K
- Exhibit 4.3
- Warrants or notes
Key figures from this report
These are the numbers Alpha Teknova reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$36.9MNo year-earlier figure tagged10-K income statement, on EDGAR
- Net income−$9.8MNo year-earlier figure tagged10-K income statement, on EDGAR
- Diluted EPS−$0.61No year-earlier figure tagged10-K income statement, on EDGAR
- Cash and cash equivalents$87.5MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$9.1MNo year-earlier figure tagged10-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2835 and related industry codes: the same peer list as the financial tables.
- Merus MRUS
- Avalo Therapeutics AVTX public float $54M, Jun 30, 2025
- Cue Biopharma CUE public float $52M, Jun 30, 2025
- Fitlife Brands FTLF public float $51M, Jun 30, 2025
- Immucell ICCC public float $51M, Jun 30, 2025
